A NEW PUBLICATION ON THE POTENTIAL OF IPSCS
The April issue of the European Biopharmaceutical Review includes a thought leadership article authored by Thomas Marx and Boris Greber. In it, they explore the potential of induced pluripotent stem cells as meticulously defined starting materials for advanced therapies.
They also introduce compelling arguments for how an off-the-shelf material, like the HLA-homozygous cell lines that RheinCell offers, eliminates variability that hampers advancement in development and complicates manufacturing.
Read the article on the RheinCell LinkedIn profile.